{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T06:00:07Z","timestamp":1785218407285,"version":"3.55.0"},"reference-count":143,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The therapeutic landscape for advanced non-small cell lung cancer (NSCLC) has been transformed by immune checkpoint inhibitors (ICIs), yet significant response heterogeneity necessitates robust, dynamic predictive biomarkers. Conventional tissue-based markers, such as PD-L1 expression and tumor mutational burden (TMB), are hindered by their invasive nature and inability to capture the dynamic tumor-host immune interplay. This review synthesizes the paradigm shift toward a dynamic, multi-parametric framework for precision immuno-oncology. We highlight the clinical utility of the liquid biopsy toolbox\u2014including circulating tumor DNA (ctDNA) for molecular residual disease (MRD) monitoring, circulating tumor cells (CTCs), and extracellular vesicles (EVs) in reflecting systemic immune status. Furthermore, we explore biological insights from multi-omics profiling, covering genomic drivers of resistance (e.g., STK11\/KEAP1), immunometabolic crosstalk, and systemic inflammatory indicators like the NLR\/PLR ratio. The potential of radiomics and pathomics to extract spatial signatures via artificial intelligence (AI) is discussed to address whole-tumor heterogeneity. Finally, we emphasize the integration of these disparate data streams through multimodal AI and Explainable AI (XAI) to construct high-fidelity predictive models. This integrated approach aims to overcome standardization hurdles and enable personalized, adaptive management in NSCLC immunotherapy.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1900900","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T05:34:22Z","timestamp":1785216862000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Evolving non-invasive biomarkers in NSCLC immunotherapy: integrating liquid biopsy and multi-omics profiling for precision oncology"],"prefix":"10.3389","volume":"17","author":[{"given":"Qiaoyi","family":"Shen","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibo","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nature25183","article-title":"The biology and management of non-small cell lung cancer","volume":"553","author":"Herbst","year":"2018","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/srep13110","article-title":"Development of PD-1\/PD-L1 pathway in tumor immune microenvironment and treatment for non-small cell lung cancer","volume":"5","author":"He","year":"2015","journal-title":"Sci Rep"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01497","article-title":"First-line immunotherapy for non-small-cell lung cancer","volume":"40","author":"Reck","year":"2022","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.004","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br J Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.569202","article-title":"The role of intratumor heterogeneity in the response of metastatic non-small cell lung cancer to immune checkpoint inhibitors","volume":"10","author":"Nico\u015b","year":"2020","journal-title":"Front Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s40425-019-0768-9","article-title":"The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors","volume":"7","author":"Davis","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-14-0983","article-title":"PD-L1 expression as a predictive biomarker in cancer immunotherapy","volume":"14","author":"Patel","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(16)30406-5","article-title":"Predictive biomarkers for checkpoint inhibitor-based immunotherapy","volume":"17","author":"Gibney","year":"2016","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1038\/s41467-021-21615-4","article-title":"Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling","volume":"12","author":"Lauren","year":"2021","journal-title":"Nat Commun"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-21-388","article-title":"PD-L1 expression in non-small cell lung cancer: heterogeneity by pathologic types, tissue sampling and metastasis","volume":"13","author":"Xuxia","year":"2021","journal-title":"J Thorac Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"7005","DOI":"10.1038\/s41467-021-27303-7","article-title":"Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer","volume":"12","author":"Clemens","year":"2021","journal-title":"Nat Commun"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.75.3384","article-title":"Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing","volume":"36","author":"Rizvi","year":"2018","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.10.019","article-title":"Tumor mutational burden as a pan-cancer biomarker for immunotherapy: the limits and potential for convergence","volume":"38","author":"Antonio","year":"2020","journal-title":"Cancer Cell"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02163-w","article-title":"Persistent mutation burden drives sustained anti-tumor immune responses","volume":"29","author":"Noushin","year":"2023","journal-title":"Nat Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4191","article-title":"Classification and characterization of microsatellite instability across 18 cancer types","volume":"22","author":"Hause","year":"2016","journal-title":"Nat Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.683419","article-title":"FDA-approved and emerging next generation predictive biomarkers for immune checkpoint inhibitors in cancer patients","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/s41419-023-05757-5","article-title":"Liquid biopsy on the horizon in immunotherapy of non-small cell lung cancer: current status, challenges, and perspectives","volume":"14","author":"Yang","year":"2023","journal-title":"Cell Death Dis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2024.07.004","article-title":"Overview of the role of liquid biopsy in non-small cell lung cancer (NSCLC)","volume":"36","author":"Ospina","year":"2024","journal-title":"Clin Oncol R Coll Radiol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s40364-021-00348-y","article-title":"Liquid biopsy to identify biomarkers for immunotherapy in hepatocellular carcinoma","volume":"9","author":"Ao","year":"2021","journal-title":"biomark Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.06.017","article-title":"Liquid biopsy for advanced NSCLC: a consensus statement from the International Association for the Study of Lung Cancer","volume":"16","author":"Rolfo","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.103798","article-title":"Machine learning for multi-omics data integration in cancer","volume":"25","author":"Cai","year":"2022","journal-title":"iScience"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/s41467-017-00965-y","article-title":"Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors","volume":"8","author":"Adalsteinsson","year":"2017","journal-title":"Nat Commun"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.curpro.2025.100029","article-title":"NSUN2\/FOXM1 positive feedback pathway promotes the Malignant development of non-small cell lung cancer","volume":"22","author":"Wang","year":"2025","journal-title":"Curr Proteomics"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.curpro.2025.100060","article-title":"The progress and prospects of single-cell sequencing, multi-omics integration analysis, and immunotherapy targeting strategies in lung cancer research","volume":"22","author":"Song","year":"2025","journal-title":"Curr Proteomics"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.curpro.2025.100033","article-title":"Antioxidant defense gene expression associated with lung cancer pathology: implications for diagnostic and therapeutic targets","volume":"22","author":"Chen","year":"2025","journal-title":"Curr Proteomics"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3233\/tub-220044","article-title":"Circulating tumor DNA (ctDNA) as a biomarker for lung cancer: early detection, monitoring and therapy prediction","volume":"46","author":"Duffy","year":"2024","journal-title":"Tumour Biol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-21-1718","article-title":"Current and future clinical applications of ctDNA in immuno-oncology","volume":"82","author":"Stadler","year":"2022","journal-title":"Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/genes16080954","article-title":"Beyond the tissue: unlocking NSCLC treatment potential through liquid biopsy","volume":"16","author":"Kontic","year":"2025","journal-title":"Genes Basel"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2020.01.09","article-title":"Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer","volume":"9","author":"Zhu","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241310803","article-title":"Liquid biopsy in NSCLC: an investigation with multiple clinical implications","volume":"24","author":"Bertoli","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B39","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.trsl.2024.05.014","article-title":"Unlocking the future of cancer diagnosis - promises and challenges of ctDNA-based liquid biopsies in non-small cell lung cancer","volume":"272","author":"Reina","year":"2024","journal-title":"Transl Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.671874","article-title":"The role of circulating tumor DNA in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.37349\/etat.2024.00280","article-title":"The promises and perils of circulating tumor DNA for monitoring immunotherapy response in non-small cell lung cancer","volume":"5","author":"Hebert","year":"2024","journal-title":"Explor Target Antitumor Ther"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.725938","article-title":"Application of circulating tumor DNA as a biomarker for non-small cell lung cancer","volume":"11","author":"Yang","year":"2021","journal-title":"Front Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlb.2025.100449","article-title":"Cancer in a drop: liquid biopsy highlights from the World Conference on Lung Cancer (WCLC) 2025","volume":"10","author":"Ghazali","year":"2025","journal-title":"J Liq Biopsy"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-022-02379-1","article-title":"Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer","volume":"41","author":"de Miguel-Perez","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2024.04.004","article-title":"Implementing circulating tumor DNA as a prognostic biomarker in resectable non-small cell lung cancer","volume":"10","author":"Abbosh","year":"2024","journal-title":"Trends Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.20944\/preprints202507.2581.v1","article-title":"Utility and future perspectives of circulating tumor DNA analysis in non-small cell lung cancer patients in the era of perioperative chemo-immunotherapy","volume":"14","author":"Ohara","year":"2025","journal-title":"Cells"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-01826-7","article-title":"The hype around ctDNA guiding an informed perioperative therapeutic strategy in early-stage non-small cell lung cancer","volume":"16","author":"Passarella","year":"2025","journal-title":"Discov Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1177\/00368504251383055","article-title":"Molecular advances in early-stage and locally advanced non-small cell lung carcinoma: shaping the future of precision oncology-systematic review","volume":"108","author":"Hassan","year":"2025","journal-title":"Sci Prog"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17040652","article-title":"Immune checkpoint inhibitors and targeted therapies in early-stage non-small-cell lung cancer: state-of-the-art and future perspectives","volume":"17","author":"Barcellini","year":"2025","journal-title":"Cancers Basel"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01754-x","article-title":"Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial","volume":"28","author":"Kim","year":"2022","journal-title":"Nat Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002551","article-title":"Assessing tumor heterogeneity: integrating tissue and circulating tumor DNA (ctDNA) analysis in the era of immuno-oncology - blood TMB is not the same as tissue TMB","volume":"9","author":"Fridland","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0433","article-title":"Clinical implications of circulating tumor DNA tumor mutational burden (ctDNA TMB) in non-small cell lung cancer","volume":"24","author":"Chae","year":"2019","journal-title":"Oncologist"},{"key":"B53","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13046-025-03348-0","article-title":"Low-coverage whole genome sequencing of cell-free DNA to predict and track immunotherapy response in advanced non-small cell lung cancer","volume":"44","author":"Janke","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.ircmb.2024.03.001","article-title":"Circulating tumor cells in lung cancer: integrating stemness and heterogeneity to improve clinical utility","volume":"392","author":"Beninato","year":"2025","journal-title":"Int Rev Cell Mol Biol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8070998","article-title":"Liquid biopsy for the detection of resistance mechanisms in NSCLC: comparison of different blood biomarkers","volume":"8","author":"Pasini","year":"2019","journal-title":"J Clin Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1093\/med\/1.1.med-9780198520771-div1-312","article-title":"Molecular biomarkers and liquid biopsies in lung cancer","volume":"49","author":"Sankar","year":"2022","journal-title":"Semin Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz196","article-title":"Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients","volume":"30","author":"Hofman","year":"2019","journal-title":"Ann Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.102948","article-title":"Systematic review: soluble immunological biomarkers in advanced non-small-cell lung cancer (NSCLC)","volume":"153","author":"Mildner","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13071675","article-title":"Prognostic and predictive biomarkers in non-small cell lung cancer patients on immunotherapy-the role of liquid biopsy in unraveling the puzzle","volume":"13","author":"Augustus","year":"2021","journal-title":"Cancers Basel"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0144535","article-title":"EpCAM-independent enrichment of circulating tumor cells in metastatic breast cancer","volume":"10","author":"H","year":"2015","journal-title":"PloS One"},{"key":"B61","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-025-02024-7","article-title":"Advances in CTC and ctDNA detection techniques: opportunities for improving breast cancer care","volume-title":"Breast Cancer Res","author":"Zhong","year":"2025"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/srep28010","article-title":"Characterization of different CTC subpopulations in non-small cell lung cancer","volume":"6","author":"Annkathrin","year":"2016","journal-title":"Sci Rep"},{"key":"B63","doi-asserted-by":"publisher","first-page":"8032","DOI":"10.1038\/s41598-019-44401-1","article-title":"Fast and efficient microfluidic cell filter for isolation of circulating tumor cells from unprocessed whole blood of colorectal cancer patients","volume":"9","author":"Silvina","year":"2019","journal-title":"Sci Rep"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/srep01259","article-title":"Isolation and retrieval of circulating tumor cells using centrifugal forces","volume":"3","author":"Han Wei","year":"2013","journal-title":"Sci Rep"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0159397","article-title":"High specificity in circulating tumor cell identification is required for accurate evaluation of programmed death-ligand 1","volume":"11","author":"Jennifer","year":"2016","journal-title":"PloS One"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1114041","article-title":"Research progress of extracellular vesicles as biomarkers in immunotherapy for non-small cell lung cancer","volume":"14","author":"Ge","year":"2023","journal-title":"Front Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16223729","article-title":"Profiling plasma extracellular vesicle metabotypes and miRNAs: an unobserved clue for predicting relapse in patients with early-stage NSCLC","volume":"16","author":"Bafiti","year":"2024","journal-title":"Cancers Basel"},{"key":"B68","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13073-024-01400-w","article-title":"Circular RNA landscape in extracellular vesicles from human biofluids","volume":"16","author":"Zhao","year":"2024","journal-title":"Genome Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1080\/1750743x.2025.2539060","article-title":"The role of exosomal PD-L1 in NSCLC immunotherapy","volume":"17","author":"Li","year":"2025","journal-title":"Immunotherapy"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3390\/life12122104","article-title":"Potential role of tumor-derived exosomes in non-small-cell lung cancer in the era of immunotherapy","volume":"12","author":"Tartarone","year":"2022","journal-title":"Life Basel"},{"key":"B71","doi-asserted-by":"publisher","first-page":"114519","DOI":"10.1016\/j.intimp.2025.114519","article-title":"Exosomal PD-L1 in non-small cell lung cancer: implications for immune evasion and resistance to immunotherapy","volume":"155","author":"Tarin","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1540906","article-title":"Serum extracellular vesicle microRNAs as potential biomarkers to predict pembrolizumab response and prognosis in metastatic non-small cell lung cancer patients","volume":"16","author":"Lamorte","year":"2025","journal-title":"Front Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.2147\/lctt.s539777","article-title":"Integrated multi-omics approaches for predicting immune checkpoint inhibitor response in NSCLC - insights from genomics, proteomics, and metabolomics","volume":"16","author":"Elayeh","year":"2025","journal-title":"Lung Cancer Auckl"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-013592","article-title":"Integrative multiomic profiling of cfDNA methylation and EV-miRNAs identifies immunotherapy-outcome molecular subtypes in NSCLC","volume":"14","author":"Onieva","year":"2026","journal-title":"J Immunother Cancer"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.603157","article-title":"Emerging blood-based biomarkers for predicting response to checkpoint immunotherapy in non-small-cell lung cancer","volume":"11","author":"Li","year":"2020","journal-title":"Front Immunol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13046-024-02969-1","article-title":"Blood-based biomarkers in patients with non-small cell lung cancer treated with immune checkpoint blockade","volume":"43","author":"Tsai","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1171649","article-title":"Soluble biomarkers to predict clinical outcomes in non-small cell lung cancer treated by immune checkpoints inhibitors","volume":"14","author":"Ancel","year":"2023","journal-title":"Front Immunol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2147\/lctt.s235102","article-title":"Recognizing prognostic and predictive biomarkers in the treatment of non-small cell lung cancer (NSCLC) with immune checkpoint inhibitors (ICIs)","volume":"12","author":"Giustini","year":"2021","journal-title":"Lung Cancer Auckl"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174280","article-title":"Soluble biomarkers with prognostic and predictive value in advanced non-small cell lung cancer treated with immunotherapy","volume":"13","author":"Honrubia-Peris","year":"2021","journal-title":"Cancers Basel"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25084533","article-title":"Novel blood biomarkers for response prediction and monitoring of stereotactic ablative radiotherapy and immunotherapy in metastatic oligoprogressive lung cancer","volume":"25","author":"Zafra","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123625","article-title":"Integrating circulating biomarkers in the immune checkpoint inhibitor treatment in lung cancer","volume":"12","author":"Duchemann","year":"2020","journal-title":"Cancers Basel"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11091269","article-title":"Plasma biomarkers and immune checkpoint inhibitors in non-small cell lung cancer: new tools for better patient selection","volume":"11","author":"Costantini","year":"2019","journal-title":"Cancers Basel"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003566","article-title":"Role of mass spectrometry-based serum proteomics signatures in predicting clinical outcomes and toxicity in patients with cancer treated with immunotherapy","volume":"10","author":"Park","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.2147\/cmar.s528555","article-title":"Dermatotoxicity of immune checkpoint inhibitors in advanced non-small cell lung cancer: current advances in mechanistic insights and predictive biomarker identification","volume":"17","author":"Shao","year":"2025","journal-title":"Cancer Manag Res"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13081794","article-title":"Circulating biomarkers of response and toxicity of immunotherapy in advanced non-small cell lung cancer (NSCLC): a comprehensive review","volume":"13","author":"Indini","year":"2021","journal-title":"Cancers Basel"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012288","article-title":"Genetic drivers of tumor microenvironment and immunotherapy resistance in non-small cell lung cancer: the role of KEAP1, SMARCA4, and PTEN mutations","volume":"13","author":"Paredes","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2018.12.48","article-title":"Molecular markers and prediction of response to immunotherapy in non-small cell lung cancer, an update","volume":"11","author":"Blons","year":"2019","journal-title":"J Thorac Dis"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1489977","article-title":"Biomarkers for immunotherapy resistance in non-small cell lung cancer","volume":"14","author":"Rother","year":"2024","journal-title":"Front Oncol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15123076","article-title":"Cancer cell-intrinsic alterations associated with an immunosuppressive tumor microenvironment and resistance to immunotherapy in lung cancer","volume":"15","author":"Otegui","year":"2023","journal-title":"Cancers Basel"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103891","article-title":"Clinical and technical insights of tumour mutational burden in non-small cell lung cancer","volume":"182","author":"Meri-Abad","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2018.11.102","article-title":"Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors","volume":"11","author":"Berland","year":"2019","journal-title":"J Thorac Dis"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-22-530","article-title":"Narrative review: blood and tumor biomarker testing in non-small cell lung cancer without an oncogenic driver","volume":"12","author":"Stinchcombe","year":"2023","journal-title":"Transl Lung Cancer Res"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00718-x","article-title":"At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC","volume":"20","author":"Otano","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3390\/ijms27073294","article-title":"Revisiting biomarker-guided therapy in EGFR-mutant non-small cell lung cancer with high PD-L1 expression","volume":"27","author":"Park","year":"2026","journal-title":"Int J Mol Sci"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10061237","article-title":"Multi-omics approaches for the prediction of clinical endpoints after immunotherapy in non-small cell lung cancer: a comprehensive review","volume":"10","author":"Bourbonne","year":"2022","journal-title":"Biomedicines"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1773700","article-title":"Identification of predictive biomarkers for nivolumab efficacy in non-small cell lung cancer through integrated serum lipidomics and proteomics analysis","volume":"17","author":"Hase","year":"2026","journal-title":"Front Immunol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.105094","article-title":"Multi-omics profiling of intercellular immunometabolic heterogeneity highlights in lung cancer: crosstalk mechanisms and resistance in the tumor-immune interface","volume":"219","author":"Rukonge","year":"2026","journal-title":"Crit Rev Oncol Hematol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/imcb.70114","article-title":"Defining the tumor microenvironment of non-small cell lung cancer","volume":"104","author":"Embaye","year":"2026","journal-title":"Immunol Cell Biol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.14336\/ad.2022.0407","article-title":"Tumor immune microenvironment and immunotherapy in non-small cell lung cancer: Update and new challenges","volume":"13","author":"Xing","year":"2022","journal-title":"Aging Dis"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2024.10.008","article-title":"Applications of single-cell analysis in immunotherapy for lung cancer: Current progress, new challenges and expectations","volume":"74","author":"Xiao","year":"2025","journal-title":"J Adv Res"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18081281","article-title":"Advances in multi-modal biomarkers for immunotherapy response in non-small cell lung cancer: ctDNA, microbiome, and radiomics","volume":"18","author":"Chakrabarti","year":"2026","journal-title":"Cancers Basel"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2025.189425","article-title":"Elucidating cellular origins and TME dynamic evolution in NSCLC through multi-omics technologies","volume":"1880","author":"Chao","year":"2025","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101831","article-title":"Analysis of PD1, LAG3, TIGIT, and TIM3 expression in human lung adenocarcinoma reveals a 25-gene signature predicting immunotherapy response","volume":"5","author":"Gu\u00e9gan","year":"2024","journal-title":"Cell Rep Med"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-025-02351-7","article-title":"Spatial signatures for predicting immunotherapy outcomes using multi-omics in non-small cell lung cancer","volume":"57","author":"Aung","year":"2025","journal-title":"Nat Genet"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.101934","article-title":"Spatially resolved transcriptomics reveal the determinants of primary resistance to immunotherapy in NSCLC with mature tertiary lymphoid structures","volume":"6","author":"Peyraud","year":"2025","journal-title":"Cell Rep Med"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.7150\/thno.131046","article-title":"The B-cell-autoantibody axis in lung cancer immunity","volume":"16","author":"Huang","year":"2026","journal-title":"Theranostics"},{"key":"B108","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12967-025-07625-6","article-title":"Long non-coding RNAs in the tumor immune microenvironment of non-small cell lung cancer: Mechanisms and clinical translational perspectives","volume":"24","author":"Wang","year":"2025","journal-title":"J Transl Med"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.2147\/cmar.s522136","article-title":"Advances in multimodal imaging techniques for evaluating and predicting the efficacy of immunotherapy for NSCLC","volume":"17","author":"Liu","year":"2025","journal-title":"Cancer Manag Res"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14620","article-title":"What does radiomics do in PD-L1 blockade therapy of NSCLC patients","volume":"13","author":"Cui","year":"2022","journal-title":"Thorac Cancer"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3779\/j.issn.1009-3419.2024.102.29","article-title":"Advancements in radiomics for immunotherapy of non-small cell lung cancer","volume":"27","author":"Hou","year":"2024","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.70144","article-title":"Pretreatment CT texture analysis for predicting survival outcomes in advanced nonsmall cell lung cancer patients receiving immunotherapy: A systematic review and meta-analysis","volume":"16","author":"Zhang","year":"2025","journal-title":"Thorac Cancer"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1434171","article-title":"Applications of CT-based radiomics for the prediction of immune checkpoint markers and immunotherapeutic outcomes in non-small cell lung cancer","volume":"15","author":"Zheng","year":"2024","journal-title":"Front Immunol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.657615","article-title":"Imaging biomarkers to predict and evaluate the effectiveness of immunotherapy in advanced non-small-cell lung cancer","volume":"11","author":"Liu","year":"2021","journal-title":"Front Oncol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.859323","article-title":"A machine learning model based on PET\/CT radiomics and clinical characteristics predicts tumor immune profiles in non-small cell lung cancer: A retrospective multicohort study","volume":"13","author":"Tong","year":"2022","journal-title":"Front Immunol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.annonc.2023.10.125","article-title":"Artificial intelligence for predictive biomarker discovery in immuno-oncology: A systematic review","volume":"35","author":"Prelaj","year":"2024","journal-title":"Ann Oncol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-022-00416-8","article-title":"Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer","volume":"3","author":"Vanguri","year":"2022","journal-title":"Nat Cancer"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17162679","article-title":"Clinically explainable prediction of immunotherapy response integrating radiomics and clinico-pathological information in non-small cell lung cancer","volume":"17","author":"Mitra","year":"2025","journal-title":"Cancers Basel"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.3390\/a17060254","article-title":"The quest for the application of artificial intelligence to whole slide imaging: Unique prospective from new advanced tools","volume":"17","author":"Gavino","year":"2024","journal-title":"Algorithms"},{"key":"B120","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.inffus.2022.01.001","article-title":"Data harmonisation for information fusion in digital healthcare: A state-of-the-art systematic review, meta-analysis and future research directions","volume":"82","author":"Nan","year":"2022","journal-title":"Inf Fusion"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1486310","article-title":"Artificial intelligence in lung cancer: Current applications, future perspectives, and challenges","volume":"14","author":"Huang","year":"2024","journal-title":"Front Oncol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1186\/s12935-021-02165-7","article-title":"The current issues and future perspective of artificial intelligence for developing new treatment strategy in non-small cell lung cancer: Harmonization of molecular cancer biology and artificial intelligence","volume":"21","author":"Tanaka","year":"2021","journal-title":"Cancer Cell Int"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0173-9","article-title":"Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC","volume":"16","author":"Camidge","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.2174\/0113892029406752251110100414","article-title":"Transforming cancer care: Genomic profiling, AI, and next-generation drug delivery systems","volume":"26","author":"Aggarwal","year":"2026","journal-title":"Curr Genomics"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/j.lddd.2025.100207","article-title":"Investigating the potential of Commelina benghalensis Linn. in breast cancer treatment: Insights from network pharmacology, molecular docking, and dynamic simulations","volume":"22","author":"Saha","year":"2025","journal-title":"Lett Drug Des Discov"},{"key":"B126","doi-asserted-by":"crossref","first-page":"100286","DOI":"10.1016\/j.lddd.2026.100286","article-title":"Single-cell multi-omics for biomarker discovery: Technologies, molecular mechanisms, applications and translational challenges","volume":"22","author":"Sahu","year":"2025","journal-title":"Lett Drug Des Discov"},{"key":"B127","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/s41698-025-00842-8","article-title":"Integration of multiple machine learning approaches develops a gene mutation-based classifier for accurate immunotherapy outcomes","volume":"9","author":"Shi","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1097\/js9.0000000000002839","article-title":"Non-invasive prediction of NSCLC immunotherapy efficacy and tumor microenvironment through unsupervised machine learning-driven CT radiomic subtypes: A multi-cohort study","volume":"111","author":"Guo","year":"2025","journal-title":"Int J Surg"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211006947","article-title":"Harnessing the epigenome to boost immunotherapy response in non-small cell lung cancer patients","volume":"13","author":"Gkountakos","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1563108","article-title":"Emerging research themes in ferroptosis research for non-small cell lung cancer: A bibliometric and visualized analysis","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2024.10.013","article-title":"Brief report: Methylation-based ctDNA serial monitoring correlates with immunotherapy response in NSCLC","volume":"26","author":"Hsiao","year":"2025","journal-title":"Clin Lung Cancer"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.4110\/in.2026.26.e7","article-title":"Harnessing the gut microbiota to improve cancer immunotherapy: Focus on lung cancer","volume":"26","author":"Park","year":"2026","journal-title":"Immune Netw"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb5920","article-title":"Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients","volume":"371","author":"Baruch","year":"2021","journal-title":"Science"},{"key":"B134","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1126\/science.abf3363","article-title":"Fecal microbiota transplant overcomes resistance to anti\u2013PD-1 therapy in melanoma patients","volume":"371","author":"Davar","year":"2021","journal-title":"Science"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.2147\/itt.s567238","article-title":"Emerging predictive biomarkers of immunotherapy sensitivity in patients with non-small cell lung cancer","volume":"15","author":"Gariazzo","year":"2026","journal-title":"Immunotargets Ther"},{"key":"B136","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s12672-026-04436-z","article-title":"Bibliometric analysis of research trends and hotspots in immunotherapy biomarkers for non-small cell lung cancer from 2015 to 2024","volume":"17","author":"Meng","year":"2026","journal-title":"Discov Oncol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14228021","article-title":"Redefining the diagnostic and therapeutic landscape of non-small cell lung cancer in the era of precision medicine","volume":"14","author":"Khan","year":"2025","journal-title":"J Clin Med"},{"key":"B138","doi-asserted-by":"publisher","first-page":"594","DOI":"10.21037\/tlcr-22-742","article-title":"Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review","volume":"12","author":"Tomasik","year":"2023","journal-title":"Transl Lung Cancer Res"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05509-7","article-title":"Current status and quality of radiomic studies for predicting immunotherapy response and outcome in patients with non-small cell lung cancer: A systematic review and meta-analysis","volume":"49","author":"Chen","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-025-03118-0","article-title":"Radiogenomics: Transforming lung cancer care through non-invasive imaging and genomic integration","volume":"42","author":"Shariaty","year":"2025","journal-title":"Med Oncol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.2174\/0109298665402963251022054441","article-title":"mRNA-based cancer vaccines: A review of the current scenario and future prospects","volume":"32","author":"Bhattacharya","year":"2026","journal-title":"Protein Pept Lett"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1016\/j.lddd.2026.100322","article-title":"From prediction to design: A machine learning model for de novo bioactive compounds and personalized biotherapeutics","volume":"22","author":"Mamoudou","year":"2025","journal-title":"Lett Drug Des Discov"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.2174\/0113892029387405250921211549","article-title":"Two-stage multi-view graph spectral clustering for single-cell RNASeq data","volume":"26","author":"Zhang","year":"2026","journal-title":"Curr Genomics"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1900900\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T05:34:25Z","timestamp":1785216865000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1900900\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":143,"alternative-id":["10.3389\/fimmu.2026.1900900"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1900900","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"article-number":"1900900"}}